• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 21st April 2016

Just Published: Systematic Review of Utility Weights Used in Economic Evaluations of Vaccines for Paediatric Infectious Diseases

This blog reports results of a systematic review of the sources and characteristics of utility weights used in economic evaluations of paediatric vaccines in developed countries. A new study has recently been published in Value in Health, which reports a…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

This blog reports results of a systematic review of the sources and characteristics of utility weights used in economic evaluations of paediatric vaccines in developed countries.

A new study has recently been published in Value in Health, which reports a systematic review of the sources and characteristics of utility weights used to assess the cost-effectiveness of vaccines for infectious diseases in paediatric populations. The report is authored by OHE’s Mike Herdman, Amanda Cole, and Professor Nancy Devlin, alongside colleagues from Sanofi-Pasteur.

The review looked at studies that elicited or used utility weights in cost-effectiveness analyses of vaccines in paediatric age populations with any of 17 vaccine-preventable infectious diseases. The results are presented following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology.

15 articles were identified which described the elicitation of utility weights intended for use in the populations of interest and 86 articles which employed utility weights in economic modelling studies for vaccines in those populations.

A variety of populations were used to elicit utility weights including parents and carers, the children themselves, or samples of the general population. Expert panels were also used on occasion to estimate utilities.

As regards the methods used to generate utilities, these were also quite variable and included direct measurement of preferences using a variety of preference elicitation techniques such as time trade off (TTO), contingent valuation, and willingness to pay. In other cases, utilities were obtained via the application of preference-based measures such as EQ-5D or the Health Utilities Index (HUI), with values for adult health states being applied to paediatric populations in some cases.

In modelling studies which employed utility weights, the sources of the utilities used were often not clearly described or were poorly reported, and/or based on weak underlying evidence.

Assumptions were often made when constructing the models; for example, in an economic model for influenza vaccine, it was assumed that utility weights for children would be equivalent to those of ‘otherwise healthy adults’.

In some cases, we also noted considerable variation in the utility weights assigned to the same or very similar health states. For example, in models for vaccination in pneumococcal disease, a utility weight of 0.45 was used for deafness in one study compared to a utility decrement of 0.8 used for hearing loss in another study.

We conclude that the scarcity of appropriate utility weights for vaccine-preventable infectious diseases in children and a lack of standardization in their use will hinder accurate cost-effectiveness assessments of interventions to prevent them. We recommend that more effort should be made to standardise economic evaluations in this area.

Access the full paper here.

This is a companion paper to one which was also published recently in Value in Health and which reported on the use of Patient Reported Outcomes (PROs) in Paediatric Populations with Vaccine-Preventable Infectious Diseases. Both papers are the product of the Patient-Reported Outcomes in Children with Infectious Diseases (PROCHID) project.

In recent years, members of OHE have contributed to several studies involving the development and/or use of PRO measures in younger populations, including:

  • Development [open access] and validation [open access] of the EQ-5D-Y, the version of EQ-5D for children
  • A pilot study of the valuation of EQ-5D-Y, including exploration of the effect of the ‘perspective’ adopted in valuation (currently being prepared for publication)
  • Development and validation of a condition-specific measure of HRQOL for use in short stature children [open access]
  • Development and use of a widely used, generic measure of children’s HRQOL, the KIDSCREEN [open access]
  • Exploration of socioeconomic inequalities in HRQOL in children and adolescents across Europe 

For more information on OHE’s research in this area, please contact Mike Herdman or Nancy Devlin.

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!